Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Int Clin Psychopharmacol. 2009 Jan;24(1):26–28. doi: 10.1097/YIC.0b013e32831db2e9

Table 1.

Worsening and Emergence of Suicidality in Patients Treated with Fluoxetine Versus Placebo

Variable Fluoxetine
(n=34)		 Placebo
(n=33)		 Statistic p
Worsening of Suicidality
  End of second week of treatment
    All subjects (% within group) 0 (0) 5 (17) X2 = 6.01 .014
    Ages 18–24† (% within group) 0 (0) 1 (14) X2 = 1.52 .218
  Study endpoint
    All subjects (% within group) 0 (0) 6 (19) X2 = 7.01 .010
    Ages 18–24† (% within group) 0 (0) 0 (0) -- --
  Emergence of Suicidality
    All subjects (% within group) 4 (12) 6 (19) X2 = 0.63 .429
    Ages 18–24† (% within group) 2 (17) 2 (29) X2 = 0.38 .539
†

Note. n = 17 at end week 2 (fluoxetine, n= 10; placebo, n = 7) and n = 19 for the end week 12 (study endpoint) intent-to-treat sample (fluoxetine, n= 12; placebo, n = 7).